Close Menu
Daily Guardian
  • Home
  • News
  • Politics
  • Business
  • Entertainment
  • Lifestyle
  • Health
  • Sports
  • Technology
  • Climate
  • Auto
  • Travel
  • Web Stories
What's On

Runny nose? Itchy? Experts say seasonal allergies worsening due to increase in pollen

May 18, 2026

Lucideon launches new biocompatibility lab to support a new era in patient safety

May 18, 2026

Wearables in Pharma & Biotech Research and Forecasts Report 2026-2031, Company Profiles and Market Strategies of Abbott, Dexcom, and Masimo

May 18, 2026

Forex Expo Dubai Moves Forward as Scheduled in September for Largest Regional Gathering

May 18, 2026

Einride, EASE Logistics, DriveOhio, and INDOT Announce Deployment of Autonomous Electric Trucks

May 18, 2026
Facebook X (Twitter) Instagram
Finance Pro
Facebook X (Twitter) Instagram
Daily Guardian
Subscribe
  • Home
  • News
  • Politics
  • Business
  • Entertainment
  • Lifestyle
  • Health
  • Sports
  • Technology
  • Climate
  • Auto
  • Travel
  • Web Stories
Daily Guardian
Home » Ardena’s New State-of-the-Art Nanomedicine Facility Secures Full GMP Approval for Manufacturing
Press Release

Ardena’s New State-of-the-Art Nanomedicine Facility Secures Full GMP Approval for Manufacturing

By News RoomNovember 19, 20243 Mins Read
Ardena’s New State-of-the-Art Nanomedicine Facility Secures Full GMP Approval for Manufacturing
Share
Facebook Twitter LinkedIn Pinterest Email

OSS, The Netherlands, Nov. 19, 2024 (GLOBE NEWSWIRE) — Ardena, a specialist pharmaceutical Contract Development and Manufacturing Organisation (CDMO) with GMP facilities in Belgium, Spain, the Netherlands, and Sweden, announces the full Good Manufacturing Practice (GMP) approval of its expanded nanomedicine facility in Oss. Granted by the Dutch Healthcare Authority, the approval enables GMP manufacturing operations for nanomedicines, marking a major milestone in Ardena’s mission to support clients in bringing innovative therapies to clinic and to market.

The approval follows a €20 million investment in a state-of-the-art 45,000 sqft facility offering GMP-compliant Grade C and Grade D cleanrooms designed specifically for nanomedicine manufacturing. The fit-for-purpose cleanrooms, alongside additional GMP production spaces, dedicated laboratories for process development and analytical capabilities, and advanced warehouse facilities, reflect Ardena’s commitment to meeting stringent regulatory standards, including the latest updates to Annex 1 for the manufacture of sterile products.

Jeremie Trochu, CEO of Ardena, commented: “Achieving full GMP approval for our manufacturing operations is a significant step forward for Ardena. This accomplishment underscores our commitment to equipping clients with world-class capabilities for the development and manufacturing of complex nanomedicine formulations. We are proud of our team’s dedication to maintaining the highest regulatory and quality standards.”

The expanded capabilities include manufacturing and GMP release of nanomedicines. These products include advanced nanoparticulate drug delivery systems, as well as imaging agents and tissue engineering products. The facility is equipped to handle a wide range of nanomedicines, including lipid-based nanoparticles (such as LNP’s, liposomes, and lipid micelles), polymeric nanoparticles (such as polymer micelles and dendrimer-based nanoparticles), and metal/metal oxide nanoparticles (such as gold, silica, and iron oxide nanoparticles).

The Oss facility also includes purpose-built automated manufacturing flows, and fully integrated analytical capabilities for characterizing complex nanomedicine formulations. These enhancements allow Ardena to scale its operations while maintaining the highest standards of quality, productivity, and client satisfaction.

“Our nanomedicine facility is one of the very few CDMO sites worldwide dedicated exclusively to nanomedicine development and manufacturing,” Trochu added. “We are uniquely positioned to meet the evolving needs of this fast-growing sector. This achievement exemplifies Ardena’s ability to deliver cutting-edge solutions and support our clients in bringing life-changing therapies to patients.”

Ardena’s nanomedicine capabilities are further bolstered by its integrated service offering. Trochu added: “We support nanomedicine projects with a fully integrated approach, including aseptic fill-finish capabilities and bioanalysis expertise. This in-house combination enables seamless, end-to-end support for clinical supply, a critical advantage for injectable nanomedicine formulations.”

For more information on Ardena’s nanomedicine capabilities, please visit https://nanomedicines.ardena.com/

About Ardena

Ardena is a leading Contract Development and Manufacturing Organization in advanced drug development of new, innovative, and complex molecules. Ardena’s mission is to enable current and next-generation therapies to get into the clinic and to patients faster. Ardena assists biopharmaceutical companies in navigating through the drug discovery and development process to create effective and compliant drug substances and products for clinical trials, by providing integrated services including solid state chemistry, API, and nanomedicine development and manufacturing, analytical and formulation development, drug product manufacturing, bioanalytical and CMC regulatory services.

A photo accompanying this announcement is available at https://www.globenewswire.com/NewsRoom/AttachmentNg/d1a45dde-e9da-4b1a-a233-9720be060297


Share. Facebook Twitter Pinterest LinkedIn Tumblr Email

Keep Reading

Lucideon launches new biocompatibility lab to support a new era in patient safety

Wearables in Pharma & Biotech Research and Forecasts Report 2026-2031, Company Profiles and Market Strategies of Abbott, Dexcom, and Masimo

Forex Expo Dubai Moves Forward as Scheduled in September for Largest Regional Gathering

Einride, EASE Logistics, DriveOhio, and INDOT Announce Deployment of Autonomous Electric Trucks

All OEMs raise their scores: First time in Working Relations Index® history

Basis and DAX United States Partner to Give Political Advertisers Exclusive Access to Premium Audio Inventory

Victoria’s Secret & Co. Issues Letter to Shareholders Highlighting Strong Performance, Significant Shareholder Value Creation and Continued Momentum Under Current Leadership

Barnes & Noble College Launches Enhanced Gift Card Program to Elevate the Campus Store Experience

Bitget Hosts ‘Summer Camp’ for Global Leaders and KOLs in South East Asia

Editors Picks

Lucideon launches new biocompatibility lab to support a new era in patient safety

May 18, 2026

Wearables in Pharma & Biotech Research and Forecasts Report 2026-2031, Company Profiles and Market Strategies of Abbott, Dexcom, and Masimo

May 18, 2026

Forex Expo Dubai Moves Forward as Scheduled in September for Largest Regional Gathering

May 18, 2026

Einride, EASE Logistics, DriveOhio, and INDOT Announce Deployment of Autonomous Electric Trucks

May 18, 2026

Latest News

All OEMs raise their scores: First time in Working Relations Index® history

May 18, 2026

Basis and DAX United States Partner to Give Political Advertisers Exclusive Access to Premium Audio Inventory

May 18, 2026

Victoria’s Secret & Co. Issues Letter to Shareholders Highlighting Strong Performance, Significant Shareholder Value Creation and Continued Momentum Under Current Leadership

May 18, 2026
Facebook X (Twitter) Pinterest TikTok Instagram
© 2026 Daily Guardian Canada. All Rights Reserved.
  • Privacy Policy
  • Terms
  • Advertise
  • Contact

Type above and press Enter to search. Press Esc to cancel.

Go to mobile version